NCT06682728

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients with Muscle-Invasive Urothelial Carcinoma At High-Risk for Recurrence

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.

Conditions

• Urothelial Carcinoma
• Muscle-invasive Bladder Cancer

Interventions

Type	Name	Description
DRUG	Sacituzumab Govitecan (SG)	Given IV
DRUG	Nivolumab	Given IV

Timeline

• Start date: 2024-11-15
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-11-12
• Last updated: 2025-03-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study